A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Completed · Phase 2

Conditions studied: Alcohol Hepatitis

In brief

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)

Key facts

Study ID

NCT06685692

Run by

Aldeyra Therapeutics, Inc.

People needed

4

Starts

2024-11-04

Expected to finish

2025-06-18

Last updated by the study team

2026-06-03

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult ≥ 21 years old on the day of signing the informed consent form;
• Clinical diagnosis of alcoholic hepatitis, based on clinical features and laboratory testing, confirmed by the Investigator at screening
• Agreement to abstain from alcohol and utilize resources to cease at-risk behaviors during the trial, including addiction/alcohol abuse treatment
• Ability and willingness to swallow tablets
• Willingness to provide signed informed consent, prior to any trial-related procedures and willingness to comply with the trial procedures and requirements

You may not qualify if…

• Pregnant, intending to become pregnant (or father a child), or breastfeeding
• Current or recent enrollment in another interventional trial in the 30 days prior to screening

Where it is running

• Synergry Healthcare — Bradenton, Florida, United States
• Florida Health Sciences Center/Tampa General Hospital/USF — Tampa, Florida, United States
• The Liver Institute at Methodist Dallas Medical Center — Dallas, Texas, United States
• UDL Clinical Research, LLC — Houston, Texas, United States
• Methodist Specialty and Transplant Hospital — San Antonio, Texas, United States
• Bon Secours Liver Institute of Newport News — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.